In patients undergoing CABG, the primary composite occurred in 5.1% with acadesine versus 5.0% with placebo, with odds ratio 1.01.
In plain wordsIn CABG patients, acadesine did not reduce the primary composite of death, stroke or support for severe heart dysfunction versus placebo.
- Peptide
- AICAR (acadesine)
- Outcome
- No significant changeDeath, nonfatal stroke or mechanical support for SLVD through day 28
- Study
n = 2,986
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- 0.1 mg/kg per minute · 7 hoursAs given in this study (human).
Measurements
- Primary outcome
- 76 participants
- acadesine
- Primary outcome
- 5.1%
- acadesine
- Primary outcome
- 75 participants
- placebo
- Primary outcome
- 5%
- placebo
- Odds ratio
- 1.01 ratio
- acadesine versus placebo
- 95% CI lower
- 0.73 ratio
- odds ratio
- 95% CI upper
- 1.41 ratio
- odds ratio
Source sentences
The primary outcome occurred in 75 of 1493 participants (5.0%) in the placebo group and 76 of 1493 (5.1%) in the acadesine group (odds ratio, 1.01 [95% CI, 0.73-1.41]).
3 context sentences(design, population, supporting numbers)
Composite of all-cause mortality, nonfatal stroke, or need for mechanical support for SLVD during and following CABG surgery through postoperative day 28.
The Reduction in Cardiovascular Events by Acadesine in Patients Undergoing CABG (RED-CABG) trial, a randomized, double-blind, placebo-controlled, parallel-group evaluation of intermediate- to high-risk patients (median age, 66 years) undergoing nonemergency, on-pump CABG surgery at 300 sites in 7 countries.
Eligible participants were randomized 1:1 to receive acadesine (0.1 mg/kg per minute for 7 hours) or placebo (both also added to cardioplegic solutions) beginning just before anesthesia induction.